Ceftibuten/Clavulanate

头孢布烯/克拉维酸盐

Report date: 2026/04/21 10:19:51

QIDP

Base Information

Drug NameCeftibuten/Clavulanate

Drug Alias Name头孢布烯+克拉维酸ACHN-383 + ACHN-789克拉维酸/头孢布烯beta-lactam + beta-lactamase inhibitor (oral, Enterobacteriaceae/complicated urinary tract infections), AchaogenACHN-383 + ACHN-789 (oral, Enterobacteriaceae/complicated urinary tract infections), Achaogen +[12]

ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibiotics

Mechanisms of ActionCell wall inhibitorsBacterial penicillin-binding protein inhibitors

TargetsBacterial penicillin-binding protein

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsYes Ceftibuten Dihydrate

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAchaogen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAchaogen Inc

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A